Healthcare entity
Every one of those 2 sits in a single category, market-trends. Of the tracked stories, 2 of 2 also mention Rigel Pharmaceuticals, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, market-trends. Of the tracked stories, 2 of 2 also mention Rigel Pharmaceuticals, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.8 for that window. Tavalisse appears in 2 tracked Healthcare stories published from March 2, 2026 through March 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 54 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tavalisse. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Rigel and Cumberland Pharmaceuticals reported Q4 results highlighting steady commercial growth in specialty oncology and hospital-based therapies. Both companies are prioritizing portfolio optimization and pipeline advancement to navigate a competitive biotech landscape.
Source: finance.yahoo.com · finance.yahoo.com
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
Tavalisse is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
